Top Markets
#1 MON MON +2,757.44%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +46.60%
#4 eCash eCash +31.94%
#5 Siren Siren +23.75%
#6 SAFEcoin SAFEcoin +19.98%
#7 Janction Janction +18.96%
#8 PinGo PinGo +15.95%
#9 Velvet Velvet +15.57%
#10 Beldex Beldex +13.32%
Coin of the day
MON MON
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rang in aandelen #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aandeelprijs
$0.30780727
Marktkapitalisatie
$94.19M
Verandering (1 dag)
-0.19%
Verandering (1 jaar)
-34.73%
Land
FR
Handel Sensorion SA (ALSEN)

Categorie

Healthcare
P/B-ratio voor Sensorion SA (ALSEN)
P/B-ratio op July 2026 TTM: 1.60
Volgens de meest recente financiële rapporten en aandelenkoers van Sensorion SA is de huidige P/B-ratio (TTM) 1.60. Eind 2023 had het bedrijf een P/B-ratio van 1.72.
P/B-ratiohistoriek voor Sensorion SA van 2011 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) 1.60 -36.00%
2024 2.50 45.20%
2023 1.72 27.66%
2022 1.35 -61.30%
2021 3.49 123.40%
2020 1.56 30.96%
2019 1.19 -63.54%
2018 3.27 -14.29%
2017 3.82 0.09%
2016 3.81 33.08%
2015 2.87 -106.25%
2014 -45.83 271.31%
2013 -12.34 -102.18%
2012 567.35 254.28%
2011 160.14 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 6.8826 330.16%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5189 307.43%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.0637 28.98%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.5808 186.30%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.7629 385.18%
NL